Corbus Pharmaceuticals Holding (CRBP)
Healthcare
Biotechnology
9.00 $
-0.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Corbus Pharmaceuticals Holding (CRBP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.3% of the shares are freely tradable; institutional investors hold 72.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
72.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
77.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
19Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Cormorant Asset Management, LLC | 12.66 | 2,344,971 | +0.0 | 03/31/2026 |
| Orbimed Advisors, LLC | 9.38 | 1,737,287 | +8.8 | 03/31/2026 |
| Aberdeen Group PLC | 7.13 | 1,321,750 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.64 | 859,407 | +40.4 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.96 | 734,106 | +0.0 | 03/31/2026 |
| Citadel Advisors Llc | 3.92 | 727,060 | -13.8 | 03/31/2026 |
| Prosight Management, LP | 3.76 | 697,108 | +1.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| abrdn Healthcare Investors | 4.20 | 778,031 | +0.0 | 05/31/2026 |
| abrdn Life Sciences Investors | 2.93 | 543,719 | +0.0 | 05/31/2026 |
| Biotech Growth Ord | 2.91 | 538,600 | +0.0 | 02/28/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.